Alluvi, formerly BI 4744, represents a significant development in weight management treatment. This dual agonist targeting both GLP-1 and GIP sites demonstrates compelling effectiveness in patient studies, possibly https://thefairlist.com/story12422176/alluvi-a-in-depth-dive-into-the-medication-s-potential